التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis. |
| المؤلفون: |
Luo, Yingying, Xia, Jun, Zhao, Zhan, Chang, Yaping, Bee, Yong Mong, Nguyen, Khue Thy, Lim, Soo, Yabe, Daisuke, McGill, Margaret, Kong, Alice Pik Shan, Chan, Siew Pheng, Deodat, Marisa, Deerochanawong, Chaicharn, Suastika, Ketut, Xu, Chenchen, Chen, Liming, Chen, Wei, Li, Xiaoying, Zhao, Weigang, Yao, Xiaomei |
| المصدر: |
Journal of Diabetes; May2023, Vol. 15 Issue 5, p419-435, 17p |
| مصطلحات موضوعية: |
DRUG dosage, INSULIN therapy, TYPE 2 diabetes, GLYCOSYLATED hemoglobin, GLYCEMIC control |
| الملخص (بالإنجليزية): |
Aims: To investigate the effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins in insulin‐naïve patients with type 2 diabetes mellitus. Methods: MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from January 2000 to February 2022. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were followed and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was adopted. The registration ID is CRD42022319078 in PROSPERO. Results: Among 11 163 citations retrieved, 35 publications met the planned criteria. From meta‐analyses and network meta‐analyses, we found that when injecting basal insulin regimens at bedtime, the optimal choice in order of most to least effective might be glargine U‐300 or degludec U‐100, glargine U‐100 or detemir, followed by neutral protamine hagedorn (NPH). Injecting glargine U‐100 in the morning may be more effective (ie, more patients archiving glycated hemoglobin < 7.0%) and lead to fewer hypoglycemic events than injecting it at bedtime. The optimal starting dose for the initiation of any basal insulins can be 0.10–0.20 U/kg/day. There is no eligible evidence to investigate the optimal maintenance dose for basal insulins. Conclusions: The five basal insulins are effective for the target population. Glargine U‐300, degludec U‐100, glargine U‐100, and detemir lead to fewer hypoglycemic events than NPH without compromising glycemic control. [ABSTRACT FROM AUTHOR] |
| Abstract (Chinese): |
摘要 目的:探讨5种基础胰岛素治疗在尚未接受胰岛素治疗的2型糖尿病(T2DM)患者的有效性、安全性、最佳起始剂量、最佳维持剂量范围及空腹血糖目标。 方法:检索2000年1月至2022年2月MEDLINE、EMBASE、Web of Science、Cochrane Library等数据库。遵循系统综述和meta分析的首选报告项目(PRISMA)指南并采用建议、评估、发展和评价的分级(GRADE)方法。在PROSPERO的注册ID为CRD42022319078。 结果:共检索到文献11163篇, 符合纳入标准的文献35篇。从meta分析和网络meta分析中, 我们发现, 在睡前注射基础胰岛素方案时, 最优选择可能是甘精胰岛素U‐300或德谷胰岛素U‐100、甘精胰岛素U‐100或地特胰岛素, 其次是低精蛋白锌胰岛素(NPH)。与睡前注射相比, 早晨注射甘精胰岛素U‐100可能更有效(即更多患者能够实现HbA1c<7.0%), 且低血糖事件更少。任何基础胰岛素起始的最佳起始剂量可为0.10‐0.20 U/kg/天。没有合适的证据来研究基础胰岛素的最佳维持剂量。 结论:5种基础胰岛素对目标人群有效。与NPH相比, 甘精胰岛素U‐300、德谷胰岛素U‐100、甘精胰岛素U‐100和地特胰岛素在不影响血糖控制的情况下可减少低血糖事件。 [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Diabetes is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder